依替米星治疗呼吸机相关性肺炎的临床疗效

Clinical evaluation of etimicin for the treatment of ventilator-associated pneumonia

目的 :评价依替米星治疗呼吸机相关性肺炎 (VAP)的疗效和安全性。方法 :以依替米星 ( 2 0 0～ 30 0mg·d-1,分 2～ 3次 ,ivgtt,一般使用 5～ 10d)治疗 2 1例呼吸机相关性肺炎 ,年龄 ( 5 1± 9)a ,平均机械通气为 ( 14± 9)d。同时对深部痰标本进行细菌培养和药敏试验。结果 :痊愈 12例 ( 5 7 1% ) ,显效 4例 ( 19 1% ) ,进步 2例 ( 9 5 % ) ,无效 3例 ( 14 3% )。临床总有效率为76 2 %。细菌培养共获 2 1株菌株 ,以革兰阴性菌为主 ,绿脓假单胞菌、大肠埃希菌、阴沟肠杆菌和肺炎克雷伯菌常见 ,其中 15株清除 ,细菌清除率为 71 4 %。不良反应轻微 ,仅 1例出现皮疹。结论

AIM:To evaluate the efficacy and safety of etimicin for the treatment of ventilator associated pneumonia METHODS:Twenty one patients with ventilator associated pneumonia received etimicin at the dose of 200 300 mg·d -1 by intravenous infusion The duration of treatment was 5 10 d,aged (51±9) a,mean duration of mechanic ventilation was (14±9) d Endotracheal aspirates were obtained and analysed in all patients RESULTS:Twelve patients (57 1%) were cure,4 patients (19 1%)marked improvement,2 (9 5%) mild improvement,3 (14 3%) failed The total clinical efficacy rate of etimicin was 76 2% Aspirates bacteria culture showed that G negative infections were prominent The most common isolated stains were Pseudomonas aeruginosa,Escherichia coli,Enterbacter cloacae and Klebsiella The bacterial clearance rates were 71 4% It showed mild adverse drug reactions CONCLUSION:Intravenous etimicin is effective in treating ventilator associated pneumonia